NCT04074577

Brief Summary

The purpose of this project is to examine the role of machine learning and computer aided diagnostics in automatic polyp detection and to determine in real-time how a computer-aided detection (CADe) algorithm will perform when compared to standard screening or surveillance colonoscopy alone. Design will be a multi-center, prospective, unblinded randomized tandem colonoscopy study. 196 patients referred for either screening or surveillance colonoscopy will be included.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 29, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 30, 2019

Completed
1.1 years until next milestone

Study Start

First participant enrolled

September 17, 2020

Completed
27 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 14, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 14, 2020

Completed
Last Updated

June 29, 2021

Status Verified

June 1, 2021

Enrollment Period

27 days

First QC Date

August 29, 2019

Last Update Submit

June 28, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of adenomas detected in combination technique compared to adenomas detected in standard technique Measured by Adenoma Miss Rate (AMR)

    AMR will be calculated as the number of adenomas detected on the second pass or portion in either group divided by the total number of adenomas detected during both passes.

    1 Year

Study Arms (2)

Standard Technique followed by Combination

ACTIVE COMPARATOR

Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. The first colonoscopy will be performed without automated polyp detection software (standard technique) followed immediately by another colonoscopy with automated polyp detection software (combination technique).

Diagnostic Test: Standard technique First

Combination +followed by Standard Technique

ACTIVE COMPARATOR

Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. In this arm, the first colonoscopy with be performed with automated polyp detection software (combination technique) followed immediately by another colonoscopy without automated polyp detection software (standard technique)

Diagnostic Test: combination technique First

Interventions

colonoscopy without automated polyp detection software

Standard Technique followed by Combination

automated polyp detection software

Combination +followed by Standard Technique

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients presenting to the endoscopy unit for a screening colonoscopy or a surveillance colonoscopy
  • Willingness to undergo tandem colonscopies with and without the use of computer-aided software while undergoing conventional colonoscopy with sedation
  • Ability to provide written, informed consent (approved by IRB) and understand the responsibilities of trial participation

You may not qualify if:

  • People with diminished cognitive capacity
  • Patients undergoing diagnostic colonoscopy (e.g. as an evaluation for active GI bleed)
  • Patients with incomplete colonoscopies (those where endoscopists did not successfully intubate the cecum due to technical difficulties or poor bowel preparation)
  • Patients that have standard contraindications to colonoscopy in general (e.g. documented acute diverticulitis, fulminant colitis and known or suspected perforation).
  • Patients with inflammatory bowel disease
  • Patients referred for endoscopic mucosal resection (EMR)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Colonic Diseases

Condition Hierarchy (Ancestors)

Intestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Seth Gross, MD

    New York Langone Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 29, 2019

First Posted

August 30, 2019

Study Start

September 17, 2020

Primary Completion

October 14, 2020

Study Completion

October 14, 2020

Last Updated

June 29, 2021

Record last verified: 2021-06

Locations